MetrioPharm AG Investor Relations News
Investor Relations News QIII 2016
Topics: Financial Calendar of MetrioPharm AG, Capital Increase, Investor Relations Perception Study, Current Status of MP1032’s Phase IIa in Psoriasis, About Us: Clinical Development.
10th Annual General Meeting of MetrioPharm AG
At the beginning, the Management and Board of MetrioPharm AG presented the 2015 annual financial statement and the progress of MetrioPharm's Research and Development projects.
MP1032 Phase II Preparation Well on Track
As reported in our last letter to you from December 2015, MetrioPharm’s phase I clinical trial on MP1032 showed excellent results.
Annual Review from the President of the Board, 2015
The year 2015 marks a major milestone for MetrioPharm. We have successfully entered the clinical phase of development for our lead drug MP1032.
Second part of Phase I Safety Study cleared by authorities
MetrioPharm AG: We have finally been able to commence clinical trials with our lead drug MP1032.
General Assembly of MetrioPharm AG 2015
In their report to the attending shareholders the management outlined the progress on the development of the company's lead product MP1032, which progressed successfully and according to plan.
MetrioPharm AG had a good start into 2015
MetrioPharm filed the application for our first clinical Study in man (Phase I) for MP1032 with the German regulatory authority BfArM.
Annual General Meeting 2014
MetrioPharm AG was delighted to welcome its shareholders on June 23, 2014, to the Annual General Meeting in Zurich.
MetrioPharm AG: Patent protection of MP1032
MetrioPharm AG was able to reach further goals with respect to the patent protection of MP1032.
Patents: Developments in all key markets
MetrioPharm AG was able to make further progress with regard to the patent protection of MP1032 in the first months of 2014.